Leonard S. Schleifer - Dec 11, 2023 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
Bd. Co-Chair, President & CEO, Director
Signature
/s/**Leonard S. Schleifer
Stock symbol
REGN
Transactions as of
Dec 11, 2023
Transactions value $
-$10,838,960
Form type
4
Date filed
12/13/2023, 04:05 PM
Previous filing
May 17, 2023
Next filing
May 15, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise +25.2K +6.95% 387K Dec 11, 2023 Direct F1
transaction REGN Common Stock Tax liability -$10.8M -12.8K -3.32% $844.09 374K Dec 11, 2023 Direct
holding REGN Common Stock 250K Dec 11, 2023 2023 GRAT
holding REGN Common Stock 5.92K Dec 11, 2023 By 401(k) Plan
holding REGN Common Stock 65K Dec 11, 2023 By Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN 2019 Performance Stock Units Options Exercise -25.2K -100% 0 Dec 11, 2023 Common Stock 25.2K Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On December 11, 2019, the reporting person was granted performance-based restricted stock units ("PSUs") representing the contingent right to receive shares of the issuer's common stock based upon the achievement of certain performance metrics related to total shareholder return ("TSR") over the applicable vesting period. On December 11, 2023, 25,155 PSUs (or the maximum number of PSUs eligible for vesting) vested in full and were automatically settled into an equal number of shares of the issuer's common stock based upon achievement of 75% cumulative TSR over the four-year performance period then ended.